Reborna Biosciences, Inc.
The name “Reborna” comes from the word of reborn and ribonucleic acid (RNA). The name contains a desire for patients and their families to feel being reborn by taking our drug for the treatment of genetic rare diseases.
Drug discovery technology
We believe that our drug discovery technology will enable to low-molecular compounds to target ribonucleic acid (RNA), a method deemed impossible to achieve with existing techniques. Harnessing this technology, we aim to provide new disease-modifying drugs for patients suffering from rare genetic diseases and their families in the future.
We will contribute the betterment of healthcare by offering new drugs that make it possible to feel being reborn for patients who suffer from genetic rare diseases and their families using our innovative drug discovery technology.
Koji Fuji - CEO/COO
President & CEO/COO: Koji Fuji
CSO: Shunya Suzuki
CTO: Koji Ono
Corporate Auditor: Noriyuki Okada
There is no current recruiting.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 Japan (Shonan Health Innovation Park)
By Train and Bus From JR Ofuna Station: Bus: Take the Enoden bus bound for Fujisawa Station Kitaguti (East Exit bus terminal, bus stop No.2) to Takeda Yakuhin-Mae stop (Approx. 15 mins) Taxi: After exiting through the South Exit, take taxi from West-side taxi terminal (Approx. 10 mins) From Fujisawa Station: Bus: Take the Enoden bus bound for Ofuna Station Higashiguchi (North Exit bus terminal, bus stop No.9) to Takeda Yakuhin-Mae stop (Approx. 15 mins) Taxi: After exiting through the North Exit, take Taxi from taxi terminal (Approx. 10 mins) By Car From Tokyo: About 11 km from the Kamiyabe Interchange on the Yokohama Bypass via Route 1 Harajuku From Odawara: About 6 km from the Fujisawa Interchange on the Shin-Shonan Bypass via Fujisawa-Bashi For More Information For inquires, contact us by e-mail: Email: email@example.com